The bronchial spasm market, projected to be valued at USD 14.99 Billion in 2025, is anticipated to grow steadily, reaching USD 22.99 Billion by 2032 at a CAGR of 6.3% during the forecast period. This growth is primarily driven by the rising prevalence of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders globally. Increasing air pollution levels, urbanization, and lifestyle-related triggers have contributed to a higher incidence of bronchial spasms, thereby fueling the market growth. Additionally, advancements in bronchodilator therapies, inhalation drug delivery systems, and growing investments in respiratory healthcare are expected to further support the market expansion. The market is also witnessing increasing adoption of personalized medicine and biologics in managing bronchospasm, particularly in severe or treatment-resistant cases.
Market Takeaways
Bronchial Spasm Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/bronchial-spasm-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 14.99 Billion |
|
Estimated Value by 2032 |
USD 22.99 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 6.3% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The bronchial spasm market is experiencing consistent growth, primarily driven by the increasing global prevalence of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. Rising exposure to environmental pollutants, allergens, smoking, and occupational hazards is significantly contributing to the surge in bronchospasm cases. This, in turn, is boosting the demand for effective treatment options, particularly bronchodilators and combination inhalation therapies. Technological advancements in inhalation drug delivery systems—such as metered-dose inhalers, dry powder inhalers, and nebulizers—are enhancing treatment efficacy and patient compliance, thus supporting market growth. Moreover, increased awareness campaigns and screening programs for respiratory diseases, especially in developing regions, are facilitating early diagnosis and timely intervention.
In September 2024, GSK announced that its monoclonal antibody therapy Nucala (mepolizumab) succeeded in reducing moderate to severe COPD exacerbations when used alongside inhaled maintenance treatment, marking significant progress in managing treatment-resistant respiratory disease.
The market is also witnessing growing interest in biologics and personalized medicine for severe or treatment-resistant cases of bronchial spasm, further expanding therapeutic options. Additionally, the rising adoption of digital health tools and telemedicine for chronic respiratory disease management is driving remote patient monitoring and medication adherence.
Regionally, robust healthcare infrastructure in developed countries and expanding access to respiratory care in emerging markets such as India and China are playing a critical role. These dynamics, along with favorable reimbursement policies and growing investments in pulmonary research and development, are expected to propel the bronchial spasm market forward throughout the forecast period.
Market Trends
Pharmaceutical companies are actively transitioning away from traditional hydrofluoroalkane (HFA) propellants toward environmentally sustainable inhaler technologies in response to tightening climate regulations and rising environmental consciousness. Inhalers, particularly metered-dose inhalers (MDIs), contribute significantly to healthcare-related greenhouse gas emissions due to their use of high-global warming potential (GWP) propellants.
In September 2024, GSK conducted final trials on HFO‑152a propellant for its Ventolin inhaler, potentially lowering its carbon footprint by over 40% with a regulatory goal of approval by 2025. Similarly, according to the same source, AstraZeneca prepared regulatory filings (EU, UK, China) for a low-carbon version of its Breztri inhaler using HFO‑1234ze, which may reduce greenhouse gas emissions by nearly 99.9%.
Rapid urbanization, rising air pollution, and increasing prevalence of respiratory disorders in Asia Pacific, Latin America, and Middle East are fueling demand for inhalation therapies. Digital respiratory devices are increasingly integrated into telehealth platforms and remote patient monitoring systems. Asia Pacific leads in projected growth, supported by expanding healthcare infrastructure and rising awareness of respiratory conditions.
In April 2024, Mundipharma and Vectura announced the progression of their long-term collaboration to reformulate Flutiform (fluticasone propionate/formoterol fumarate), a widely used pressurized metered-dose inhaler (pMDI) for asthma treatment. The reformulation aims to deliver the same therapeutic efficacy while significantly reducing the product's environmental impact. This initiative reflects growing industry efforts to transition toward sustainable inhaler technologies and aligns with global goals to lower greenhouse gas emissions from respiratory therapies.
Market Opportunities
With asthma and COPD management increasingly focused on long-term control and adherence, smart inhalers equipped with sensors, Bluetooth connectivity, and real-time tracking features are gaining momentum. These devices help monitor usage patterns, improve patient compliance, and enable personalized care through integration with mobile apps and telehealth platforms.
In February 2022, Aptar launched the HeroTracker Sense device, converting ordinary metered-dose inhalers (MDIs) into smart, connected health tools. It tracks inhalation events, flow rate, timing, and environmental factors via an app and cloud platform, enabling healthcare providers and patients to monitor adherence and inhaler technique more effectively. The product gained recognition as a Gold Winner at the InnoPack 2022 China Awards, underlining its real-world value in improving chronic respiratory care.
As environmental concerns gain prominence in the healthcare sector, pharmaceutical companies are investing in low-global warming potential (GWP) propellants for metered-dose inhalers (MDIs). This shift presents a major opportunity for innovation and differentiation in respiratory drug delivery.
In February 2022, AstraZeneca announced a strategic partnership with Honeywell to develop next-generation respiratory inhalers using the low-global warming potential (GWP) propellant HFO-1234ze, which offers up to 99.9% lower GWP than traditional propellants currently used in metered-dose inhalers (MDIs). This initiative aligns with AstraZeneca’s flagship sustainability program, Ambition Zero Carbon, and marks a significant milestone in reducing the environmental footprint of respiratory medicines. The announcement coincided with AstraZeneca's 2021 Sustainability Report, which highlighted a 59% reduction in the company’s Scope 1 and 2 greenhouse gas emissions since 2015 and confirmed that 100% of its imported electricity now comes from renewable sources, including emissions from its acquisition of Alexion.
Analyst View
Recent Key Developments
Competitive Landscape
Bronchial Spasm Market Segmentation
Regional Insights
Related Reports :